The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Strategies to prevent anthracycline-induced cardiotoxicity in cancer survivors
Open accessAbstract
Cancer diagnostics and therapies have improved steadily over the last few decades, markedly increasing life expectancy for patients at all ages. However, conventional and newer anti-neoplastic therapies can cause short- and long-term cardiotoxicity. The clinical implications of this cardiotoxicity become more important with the increasing use of cardiotoxic drugs. The implications are especially serious among patients predisposed to adverse cardiac effects, such as youth, the elderly, those with cardiovascular comorbidities, and those receiving additional chemotherapies or thoracic radiation. However, the optimal strategy for preventing and managing chemotherapy-induced cardiotoxicity remains unknown. The routine use of neurohormonal antagonists for cardioprotection is not currently justified, given the marginal benefits and associated adverse events, particularly with long-term use. The only United States Food and Drug Administration and European Medicines Agency approved treatment for preventing anthracycline-related cardiomyopathy is dexrazoxane. We advocate administering dexrazoxane during cancer treatment to limit the cardiotoxic effects of anthracycline chemotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2013 ACCF/AHA Guideline for the Management of Heart Failure
Yancy, C. W., Jessup, M., Bozkurt, B., Butler, J., Casey, D. E., Drazner, M. H., Fonarow, G. C., Geraci, S. A., Horwich, T., Januzzi, J. L., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.05.019 · Cited by 12,536
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
Pitt, B., Zannad, F., Remme, W. J., Cody, R., Castaigne, A., Perez, A., Palensky, J., & Wittes, J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909023411001 · Cited by 9,214
Prevalence of Childhood and Adult Obesity in the United States, 2011-2012
Ogden, C. L., Carroll, M. D., Kit, B. K., & Flegal, K. M. (2014) · JAMA · doi:10.1001/jama.2014.732 · Cited by 8,072
American College of Sports Medicine Roundtable on Exercise Guidelines for Cancer Survivors
Schmitz, K. H., Courneya, K. S., Matthews, C., Demark-Wahnefried, W., GALVÃO, D. A., Pinto, B. M., IRWIN, M. L., WOLIN, K. Y., SEGAL, R. J., LUCIA, A., et al. (2010) · Medicine & Science in Sports & Exercise · doi:10.1249/mss.0b013e3181e0c112 · Cited by 2,781
Defibrillator implantation in patients with nonischemic systolic heart failure
Køber, L., Thune, J. J., Nielsen, J. C., Haarbo, J., Videbæk, L., Korup, E., Jensen, G., Hildebrandt, P., Steffensen, F. H., Bruun, N. E., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1608029 · Cited by 1,763 · cited 1×
“tion of sudden cardiac death has not benefited patients with non-ischemic cardiomyopathy (LVEF ≤35%) and symptomatic systolic HF, in contrast to the successes in patients with ischemic-cardiomyopathy [147].”
ResultBluethmann, S. M., Mariotto, A. B., & Rowland, J. H. (2016) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-16-0133 · Cited by 1,146
Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis
Moslehi, J. J., Salem, J.-E., Sosman, J. A., Lebrun-Vignes, B., & Johnson, D. B. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30533-6 · Cited by 942
Bhakta, N., Liu, Q., Ness, K. K., Baassiri, M., Eissa, H., Yeo, F., Chemaitilly, W., Ehrhardt, M. J., Bass, J., Bishop, M. W., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31610-0 · Cited by 862
Statin Prescriptions and Breast Cancer Recurrence Risk: A Danish Nationwide Prospective Cohort Study
Ahern, T. P., Pedersen, L., Tarp, M., Cronin-Fenton, D. P., Garne, J. P., Silliman, R. A., Sorensen, H. T., & Lash, T. L. (2011) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djr291 · Cited by 387
Cerebrovascular disease risk in older head and neck cancer patients after radiotherapy
Smith, G. L., Smith, B. D., Buchholz, T. A., Giordano, S. H., Garden, A. S., Woodward, W. A., Krumholz, H. M., Weber, R. S., Ang, K.-K., & Rosenthal, D. I. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.6546 · Cited by 231
Cited by
The updated landscape of tumor microenvironment and drug repurposing
Jin, M.-Z., & Jin, W.-L. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00280-x · Cited by 1,262
Hecker-Nolting, S., Langer, T., Blattmann, C., Kager, L., & Bielack, S. S. (2021) · Cancer Management and Research · doi:10.2147/cmar.s287908 · Cited by 10
“Over the years, much interest has been focused on the cardioprotectant dexrazoxane.(33) The agent is believed to diminish the heart of free radicals, favored by anthracycline therapy, and associated oxidative stress and cardiac destruction.”
Background
Metadata
- Authors
- Bansal, N., Adams, M. J., Ganatra, S., Colan, S. D., Aggarwal, S., Steiner, R., Amdani, S., Lipshultz, E. R., & Lipshultz, S. E.
- Venue
- Cardio-Oncology
- Published
- 2019-12
- Volume
- 5
- Issue
- 1
- Pages
- 18-18
- ISSN
- 2057-3804 (ISSN-L)
- OpenAlex
- W2991362566
- Cited by
- 181
- References
- 11
- FWCI
- 12.55
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Strategies to prevent anthracycline-induced cardiotoxicity in cancer survivors. https://app.cochat.ai/papers/10.1186/s40959-019-0054-5
- The paper
- Bansal, N., Adams, M. J., Ganatra, S., Colan, S. D., Aggarwal, S., Steiner, R., Amdani, S., Lipshultz, E. R., & Lipshultz, S. E. (2019). Strategies to prevent anthracycline-induced cardiotoxicity in cancer survivors. Cardio-Oncology. https://doi.org/10.1186/s40959-019-0054-5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.